| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Trabedersen sodium targets transforming growth factor beta 2 (TGF-β2) mRNA through an antisense mechanism. As an antisense oligodeoxynucleotide, it specifically binds to TGF-β2 mRNA and inhibits its translation, thereby reducing TGF-β2 protein expression. TGF-β2 is a cytokine involved in immune suppression, angiogenesis, and tumor progression, making it a target for cancer research.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that Trabedersen sodium is an antisense oligodeoxynucleotide that specifically inhibits TGF-β2 expression. By binding to TGF-β2 mRNA, it prevents translation and reduces TGF-β2 protein levels. This inhibition of TGF-β2 signaling may reverse immune suppression and inhibit tumor growth. Detailed in vitro activity data, including IC50 values and knockdown efficiency, are not extensively documented in the available literature.
|
| ln Vivo |
In vivo activity of Trabedersen sodium has been investigated in the context of malignant brain tumors and other solid tumors overexpressing TGF-β2. By inhibiting TGF-β2 expression, the compound may reduce immune suppression and inhibit tumor growth. Detailed in vivo efficacy data from animal models and clinical studies are referenced in the literature. The compound is intended for research use only.
|
| Enzyme Assay |
The in vitro assay for Trabedersen sodium involves measuring its ability to inhibit TGF-β2 expression. Cells are treated with the antisense oligonucleotide, and TGF-β2 mRNA levels are measured by qPCR. TGF-β2 protein levels are measured by ELISA or Western blot. Standard protocols include appropriate controls such as scrambled oligonucleotides and vehicle controls. The compound's specificity for TGF-β2 is confirmed by assessing its effect on other TGF-β isoforms.
|
| Cell Assay |
In vitro cell-based assays for Trabedersen sodium are conducted using cancer cell lines that overexpress TGF-β2. Cells are treated with the compound at various concentrations, and TGF-β2 mRNA and protein levels are measured. The effect on cell proliferation, migration, and immune suppression is assessed. Standard protocols include appropriate controls such as scrambled oligonucleotides and vehicle controls.
|
| Animal Protocol |
In vivo animal studies for Trabedersen sodium would typically be conducted using mouse models of malignant brain tumors or other solid tumors overexpressing TGF-β2. Animals would be administered the compound via appropriate routes, and tumor growth inhibition would be monitored. TGF-β2 expression in tumor tissues would be measured. Pharmacokinetic parameters would be determined from plasma samples. Detailed protocols and efficacy data are available from the literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Trabedersen sodium are typical of antisense oligonucleotides. As a nucleic acid-based compound, it is subject to degradation by nucleases in biological fluids. Detailed pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution are not extensively documented in the available literature. The compound is intended for research use only.
|
| Toxicity/Toxicokinetics |
Toxicity information for Trabedersen sodium is limited. As a research-use compound, standard safety precautions for handling should be followed. The compound is designated for research use only and is not for human therapeutic applications. No detailed toxicity data are available from the search results.
|
| References |
|
| Additional Infomation |
Trabedersen sodium (AP 12009 sodium) is an antisense oligodeoxynucleotide that specifically inhibits TGF-β2 (TGF-beta/Smad). It is used to study malignant brain tumors and other solid tumors overexpressing TGF-β2. It is intended for research use only.
|
| Molecular Formula |
C177H217N60NA18O94P17S17
|
|---|---|
| Molecular Weight |
6174.43
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Typically soluble in DMSO (e.g. 10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.1620 mL | 0.8098 mL | 1.6196 mL | |
| 5 mM | 0.0324 mL | 0.1620 mL | 0.3239 mL | |
| 10 mM | 0.0162 mL | 0.0810 mL | 0.1620 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
